Navigation Links
Data From Phase II Trial of Prolor Biotech's Long-acting Human Growth Hormone Presented at Endo 2012
Date:6/26/2012

t forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The for
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Penn researchers study of phase change materials could lead to better computer memory
2. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
3. BioPharm Systems Launches Services to Help Phase I Clinics Implement Oracle Health Sciences LabPas
4. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
5. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
8. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
9. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
10. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
11. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... trying to justify RFID investment wholly on the basis ... in their supply chain are merely deluding themselves. In ... these areas, it means that gross inefficiencies exist in ... improvements even without applying RFID. , ,The benefits of ...
... Software is partnering with Brooktrout Technology to ... , ,The addition of Brooktrout TR1034 intelligent fax boards to ... integrate real-time fax over IP with their VoIP networks, allowing ... and migrate to an IP-based system in the future as ...
... Care , a not-for-profit network of healthcare services in ... NetScaler, Inc. , for a new high-performance network. ... usage and response time across its network of more ... care clinics, home health care services. , ,System architect ...
Cached Biology Technology:The key to finding RFID's ROI 2The key to finding RFID's ROI 3The key to finding RFID's ROI 4
(Date:4/17/2014)... Current Biology on April 17 have discovered ... Brazilian insects, which represent four distinct but related species ... example of an animal with sex-reversed genitalia. , ... animals, Neotrogla is the only example in ... Yoshizawa from Hokkaido University in Japan. , During copulation, ...
(Date:4/17/2014)... the process whereby the genetic information of DNA ... proteins, which have numerous different functions in living ... intermediary during gene expression, by relating the genetic ... in manufacturing proteins. , By examining the ... in an organism at a given time, researchers ...
(Date:4/17/2014)... full of wild animals and plant life, but there,s ... churning away in the soil, decomposing organic matter and ... role these fungi play in ecological systems, their identities ... scientists has generated a genetic map of more than ... was published this week in the Proceedings of ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Rapid and accurate mRNA detection in plant tissues 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... gases such as CO 2 , which are now known to ... for a number of years. In contrast to the atmosphere, the ... higher. In the global carbon cycle the sea ab-sorbs a proportion ... into the at-mosphere again. About half of the anthropogenic emission ...
... tomography (PET) imaging, seeing is believing: Evaluating a ... typically involves visual interpretation of scans of cancer ... indexone that reflects the reduction of metabolic activity ... responses to first-line chemotherapy, according to a study ...
... Todays Answers, Tomorrows Questions taking place in London ... brings together policymakers, researchers and natural scientists with what ... research in the field of genomics - the Economic ... DNA, genes and chromosomes are often described as ...
Cached Biology News:New ETH Zurich article published in scientific journal 'Nature' 2Quantitative PET imaging finds early determination of effectiveness of cancer treatment 2From GM farm animals to embryonic stem cell research 2From GM farm animals to embryonic stem cell research 3
... The Finnpipette BioControl is a major ... A complete liquid handling system - ... interchangeable tip cone modules. All five ... cone modules fit one handle. The ...
Sulfadimethoxine (CH-2027)...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
Biology Products: